Hikma Pharmaceuticals (UK) Today
| HIK Stock | 2,020 2.00 0.1% |
PerformanceInsignificant
| Odds Of DistressLow
|
Hikma Pharmaceuticals is trading at 2020.00 as of the 24th of March 2025, a 0.1 percent decrease since the beginning of the trading day. The stock's lowest day price was 2006.0. Hikma Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Hikma Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 221.88 M outstanding shares. More on Hikma Pharmaceuticals PLC
Moving together with Hikma Stock
Moving against Hikma Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Hikma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hikma Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hikma Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Hikma Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Hikma Pharmaceuticals' managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| Executive Chairman | Engineer Darwazah | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
| Excise Tax Activities | Animal TestingCatholic | ||||
Hikma Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Hikma Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsHikma Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hikma Pharmaceuticals' financial leverage. It provides some insight into what part of Hikma Pharmaceuticals' total assets is financed by creditors.
| |||||
Hikma Pharmaceuticals PLC (HIK) is traded on London Exchange in UK and employs 9,500 people. Hikma Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.48 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hikma Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hikma Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hikma Pharmaceuticals PLC operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 221.88 M outstanding shares.
Hikma Pharmaceuticals generates positive cash flow from operations, but has no cash available
Check Hikma Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationHikma Pharmaceuticals PLC has a total of 221.88 Million outstanding shares. Hikma Pharmaceuticals secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hikma Ownership Details
Hikma Pharmaceuticals PLC Risk Profiles
Although Hikma Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Hikma Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.9623 | |||
| Semi Deviation | 1.37 | |||
| Standard Deviation | 1.33 | |||
| Variance | 1.77 |
Hikma Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hikma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Hikma Pharmaceuticals Corporate Management
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mazen Darwazeh | Executive MENA | Profile | |
| Khalid Nabilsi | Chief Officer | Profile | |
| Hussein Arkhagha | Company Counsel | Profile | |
| Susan Ringdal | Executive Affairs | Profile | |
| Majda Labadi | Ex Devel | Profile | |
| Guy Featherstone | Associate Relations | Profile |
Other Information on Investing in Hikma Stock
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.